Tarsus Pharmaceuticals Inc (NAS:TARS)

$ 50.84 1.18 (2.38%) Market Cap: 1.94 Bil Enterprise Value: 1.70 Bil PE Ratio: 0 PB Ratio: 8.18 GF Score: 49/100

Q3 2024 Tarsus Pharmaceuticals Inc Earnings Call Transcript
Nov 13, 2024

$46.51 (-2.24%)

Earnings
Q2 2024 Tarsus Pharmaceuticals Inc Earnings Call Transcript
Aug 08, 2024

$23.61 (+4.05%)

Earnings
Q1 2024 Tarsus Pharmaceuticals Inc Earnings Call Transcript
May 08, 2024

$37.35 (-1.79%)

Earnings
Q4 2023 Tarsus Pharmaceuticals Inc Earnings Call Transcript
Feb 27, 2024

$39.22 (+18.28%)

Earnings
Q3 2023 Tarsus Pharmaceuticals Inc Earnings Call Transcript
Nov 09, 2023

$15.57 (-5.86%)

Earnings
Tarsus Pharmaceuticals Inc To Discuss XDEMVY Approved For The Treatment Of Demodex Blepharitis Call Transcript
Jul 25, 2023
Tarsus Pharmaceuticals Inc To Discuss Creating the Next Blockbuster Category in Eye Care Call Transcript
Jun 15, 2023
Tarsus Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Tarsus Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript
Mar 15, 2023
Tarsus Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 13, 2023
Tarsus Pharmaceuticals Inc To Discuss Revolutionizing Treatment For Demodex Blepharitis Patients Call Transcript
Feb 08, 2022
Tarsus Pharmaceuticals Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 08, 2021
Tarsus Pharmaceuticals Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript
Jul 14, 2021
Tarsus Pharmaceuticals Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript
Jun 22, 2021
Tarsus Pharmaceuticals Inc Saturn-1 Pivotal Trial Topline Results Call Transcript
Jun 21, 2021

Q1 2024 Tarsus Pharmaceuticals Inc Earnings Call Transcript

May 08, 2024 / 08:30PM GMT

Release Date Price: $37.35 (-1.79%)

Transcript 10-Q8-K

Operator

Good afternoon, and welcome to the Tarsus first-quarter 2024 financial results conference call. As a reminder, this call is being recorded. At this time, I would like to turn the call over to David Nakasone, Head of Investor Relations to lead off the call. Please go ahead.

David Nakasone

Tarsus Pharmaceuticals Inc - Senior Director, Investor Relations

Thank you. Before we begin, I encourage everyone to go to the Investors section of the Tarsus website to view the earnings release and related materials we will be discussing today.

Joining me on the call this afternoon are Bobak Azamian, our Chief Executive Officer and Chairman; Aziz Mottiwala, our Chief Commercial Officer; Jeff Farrow, our Chief Financial Officer and Chief Strategy Officer; and joining us for the question and answer session, Sesha Neervannan, our Chief Operating Officer.

I'd like to draw your attention to Slide 3, which contains our forward-looking statements. During this call, we will be making forward looking statements that are based on our current expectations and beliefs

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.